Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
The purpose of this study is to determine the safety and effectiveness of combination therapy
 with Proleukin and Rituxan on patients with low-grade Non-Hodgkin's Lymphoma who have
 previously failed Rituxan treatments.
Diagnosis and disease status:

 -  Subjects with CD20+, B-cell, Non-Hodgkin's lymphoma of low-grade or follicular
 histology with measurable relapsed or unresponsive disease after prior therapy; mantle
 cell and chronic lymphocytic leukemia subtypes are excluded.

 -  Subjects who previously received a single-agent course of rituximab and showed no
 tumor response, or had a response lasting < 6 months. The previously administered
 rituximab must have included at least 75% of the standard 4-week regimen (4 x 375
 mg/m2). A record of the previous rituximab treatment and response must be available as
 a source document at the site.

 Exclusion:

 -  Subjects who showed no tumor response or a response lasting <6 months to treatment
 with Rituximab in combination with Chemotherapy or another therapeutic modality
 (radiation or radioimmunoconjugates).

 -  HIV positive.

 -  Symptomatic thyroid disease requiring medical intervention other than replacement
 treatment for hypothyroidism.

 -  Clinically significant cardiac, pulmonary, and /or hepatic dysfunction (if subject has
 history of congestive heart failure or myocardial infarction, must have been stable
 for at least 6 months, and have no current symptoms

 -  If cardiac ejection fraction has been measured, it must be greater than 50%.